TriSalus Life Sciences In... (TLSI)
TriSalus Life Sciences Inc. (TLSI) Stock Price, Analysis & Data
| Bid | 3.39 |
| Market Cap | 351.59M |
| Revenue (ttm) | 45.08M |
| Net Income (ttm) | -57.25M |
| Beta | 0.43 |
| EPS (ttm) | -1.33 |
| PE Ratio (ttm) | n/a |
| Forward PE | -22.84 |
| P/B (ttm) | 53.36 |
| P/S (ttm) | 7.80 |
| Earnings Date | Nov 12, 2026 |
| Ask | 5.72 |
| Volume | 130,010 |
| Avg. Volume (20D) | 516,520 |
| Open | 5.74 |
| Previous Close | 5.74 |
| Day's Range | 5.52 - 5.82 |
| 52-Week Range | 2.20 - 7.95 |
| Analyst | Strong Buy |
| Price Target | 9.5 (66.37%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About TLSI
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures...
Financial Performance
In 2025, TriSalus Life Sciences's revenue was 45.15M, an increase of 53.41% compared to the previous year's 29.43M. Earnings were -39.23M, an increase of 30.56%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for TLSI stock is "Strong Buy". The 12-month stock price forecast is 9.5, which is upside of 66.37% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
